Condition
Late Complication From Kidney Transplant
Total Trials
4
Recruiting
0
Active
0
Completed
4
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.4% vs benchmark
Late-Stage Pipeline
25%
1 trials in Phase 3/4
Results Transparency
25%
1 of 4 completed with results
Key Signals
1 with results100% success
Data Visualizations
Phase Distribution
3Total
P 1 (1)
P 2 (1)
P 4 (1)
Trial Status
Completed4
Trial Success Rate
100.0%
Benchmark: 86.6%
Based on 4 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT02088931Phase 1CompletedPrimary
Treg Adoptive Therapy for Subclinical Inflammation in Kidney Transplantation
NCT02108600Phase 2CompletedPrimary
Tocilizumab for Renal Graft Inflammation
NCT02624349Phase 4CompletedPrimary
Immunogenicity and Safety of Human Papilloma Virus Vaccine in Solid Organ Transplant Recipients
NCT00715468CompletedPrimary
Prospective, 6 Month, Open Label, Conversion Study From Mycophenolate Mofetil (MMF) to PRMYFORTIC*
Showing all 4 trials